Overview

Topical Avastin for Treatment of Corneal Neovascularization

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Male or female, at least 18 years of age

- Clinical stable corneal neovascularization (as defined above)

- Ability to understand and provide informed consent to participate in this study and
willingness to follow study instructions and likely to complete all required visits.

- All female patients of childbearing potential will be excluded. A female is considered
to be of childbearing potential unless she is postmenopausal and without menses for 12
months or without a uterus and/or both ovaries.

Exclusion Criteria:

- Current or recent (≤ 1 month) systemic corticosteroid therapy or periocular
corticosteroid injections to the study eye

- Current or recent (≤ 3 months) intravitreal drug injection to the study eye; recent (≤
1 month) change in dose and frequency of topical steroids and/or non-steroidal
anti-inflammatory agents

- Uncontrolled hypertension defined as systolic blood pressure of ≥ 150 mmHg or
diastolic blood pressure of ≥ 90 mmHg; history of a thromboembolic event, including
myocardial infarction or cerebral vascular accident

- Patients age 75 or older; history of renal abnormalities

- Recent (≤ 3 months ) or planned surgery

- History of coagulation abnormalities, including end stage liver disease or current
anticoagulation medication other than aspirin (warfarin, heparin, enoxaparin, or
similar anticoagulant agent)

- All female patients of childbearing potential (a female is considered to be of
childbearing potential unless she is postmenopausal and without menses for 12 months
or without a uterus and/or both ovaries)

- Any condition (including language barrier) that precludes patient's ability to comply
with study requirements including completion of study